FDA approves Dynavax's HBV vaccine

Dynavax Technologies Corp. (NASDAQ:DVAX) gained $3 (15%) to $23.05 in after-hours trading Thursday after FDA approved Heplisav-B to prevent infection caused by all known subtypes of HBV in adults ages 18 and older. The company said Heplisav-B is the only two-dose HBV vaccine approved in the U.S. for adults. The vaccine is the first FDA approval for the company.

Dynavax plans to launch Heplisav-B next quarter. CEO Eddie Gray told BioCentury the company is in the process of finalizing the vaccine's price...